This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
What is methylene blue?
Methylene blue is a water-soluble blue dye and prescription drug sold as Provayblue. The FDA has approved methylene blue for only one use: acquired methemoglobinemia, a blood disorder, in adults and children. Provayblue first received FDA approval in 2016.
Often called the first synthetic drug, methylene blue started as a laboratory stain more than a century ago.
Methylene blue is a small dye molecule rather than a peptide. Even so, the drug often comes up in conversations about mitochondrial peptides.
Methylene blue's approved role depends on how the drug changes hemoglobin inside red blood cells.
How methylene blue works in methemoglobinemia
In methemoglobinemia, methylene blue returns hemoglobin's iron from the ferric (Fe3+) state back to the ferrous (Fe2+) state.
Methemoglobinemia occurs when hemoglobin's ferrous iron oxidizes to the ferric form, creating methemoglobin. Acquired forms of methemoglobinemia are the most common. The disorder can stem from genetic, dietary, toxic, or unexplained causes. Methemoglobinemia symptoms range from headache to coma and do not always track measured levels.
Methylene blue first takes an electron from NADPH, a carrier molecule produced as cells process sugar. Methylene blue then becomes colorless leucomethylene blue, which reduces the ferric iron inside red blood cells.
The NADPH pathway is only one of several enzyme systems methylene blue acts on.
Methylene blue acts on three enzyme targets beyond hemoglobin
Beyond hemoglobin, methylene blue acts on multiple molecular targets, blocking enzymes that shape brain chemistry and blood vessel tone.
- Monoamine oxidase A and B (MAO-A and MAO-B): enzymes that break down monoamines, a group of chemical messengers in the brain. In purified human enzyme studies, methylene blue is a potent, reversible MAO-A inhibitor but blocks MAO-B only at much higher concentrations. MAO-A inhibition is why methylene blue carries drug-interaction warnings.
- Nitric oxide synthase: the enzyme that makes nitric oxide, a molecule that widens blood vessels. In lab enzyme studies, methylene blue directly inhibits nitric oxide synthase.
- Soluble guanylate cyclase: the enzyme that relays nitric oxide's signal through a messenger molecule called cGMP. In the same lab work, methylene blue inhibited soluble guanylate cyclase less potently than nitric oxide synthase.
Methylene blue's ability to dampen nitric oxide signaling is why researchers have tested it in septic shock.
Methylene blue has one approved use and several investigated uses
Acquired methemoglobinemia is methylene blue's only FDA-approved use, so every other use is off-label. Evidence for those uses ranges from animal studies and case series to a few small randomized trials.
Researchers have also studied methylene blue's effects on mitochondria, the cell structures that generate energy.
Ifosfamide encephalopathy
Methylene blue is the most widely used drug for ifosfamide-induced encephalopathy, a brain dysfunction caused by the chemotherapy drug ifosfamide. Studies of methylene blue for this complication have produced mixed results.
Encephalopathy develops in 10-15% of people given ifosfamide. In one case series, four of eight patients given methylene blue recovered fully within 24 hours, while two took 72 hours. The four patients not given the drug recovered after 48 hours.
A review found only case reports and one chart review for this use. Patients not given methylene blue recovered in the same time frame as those who received it. Methylene blue's use for this complication remains controversial, and controlled trials are still needed.
Photodynamic therapy
Methylene blue is investigated as a photosensitizer, a light-activated compound, in photodynamic therapy. When light hits the dye, methylene blue produces reactive oxygen species that damage bacteria and other microbes.
Clinical case reports have tested methylene blue photodynamic therapy in skin cancers and infections. In 13 controlled animal studies of infected skin wounds, every study favored the therapy. A meta-analysis of 11 randomized trials in gum disease paired the therapy with deep dental cleaning. The combination reduced plaque, pocket depth, and bleeding but left gum attachment unchanged.
Get 100+ biomarkers tested
One blood draw a year. A full picture of your health, explained in plain language.
Get 100+ biomarkers tested
One blood draw a year. A full picture of your health, explained in plain language.
Septic shock
Methylene blue is investigated as an add-on drug in septic shock because the drug counters the nitric oxide signaling that drives dangerous blood vessel widening. Trial evidence for this use remains small and low in certainty.
| Study design | Patients | Finding | Evidence grade |
|---|---|---|---|
| Single-center randomized placebo-controlled trial, 2023 | 91 | Blood pressure drugs (vasopressors) stopped sooner, 69 vs 94 hours; 28-day mortality similar | Moderate (single trial) |
| Meta-analysis of 3 randomized trials, 2024 | 141 | Shorter ICU stay, fewer ventilation days, and earlier vasopressor discontinuation; mortality not pooled | Low to moderate |
| Meta-analysis of 5 randomized trials, 2025 | 257 | Lower mortality (odds ratio 0.49) and a 1.34 mmHg rise in mean arterial pressure | Low (mortality); very low (blood pressure) |
| Meta-analysis of 9 randomized trials, mostly septic shock, 2026 | 535 | No significant drop in short-term mortality (odds ratio 0.73); some trials reported less vasopressor use | Very low (mortality) |
| Narrative review, 2020 | Not applicable | Possible benefit if given early; more randomized trials needed | Expert opinion |
| Expert pros-and-cons review, 2024 | Not applicable | Safety and benefit not fully established; not for routine use | Expert opinion |
Larger, adequately sized trials would be needed before any off-label use of methylene blue rests on firm evidence.
IMPORTANT SAFETY INFORMATION
Methylene blue is approved by the FDA as Provayblue, an intravenous prescription drug, only for acquired methemoglobinemia in adults and children. Every other use described on this page is off-label and investigational. Methylene blue is not prescribed, sold, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.
Provayblue carries a boxed warning: methylene blue may cause serious or fatal serotonin syndrome when used with serotonergic drugs and opioids. The label advises avoiding use alongside selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and opioids.
Contraindications on the label: severe hypersensitivity to methylene blue or any other thiazine dye, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, because of the risk of hemolytic anemia.
Warnings on the label: severe allergic reactions, including anaphylaxis; methemoglobinemia that does not resolve after 2 doses or rebounds; hemolytic anemia, which may appear 1 or more days after a dose; underestimated oxygen saturation readings on pulse oximetry; confusion, dizziness, and vision changes that affect driving and operating machinery; and interference with urine tests that rely on a blue indicator. Methylene blue may cause fetal harm in pregnancy, and the label advises stopping breastfeeding during and for up to 8 days after a dose.
Most common side effects on the label (more than 2%): headache, low potassium, diarrhea, low magnesium, muscle jerks (myoclonus), nausea, and seizure-like phenomena. The FDA-approved Provayblue prescribing information is the authoritative label.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
References
- DailyMed (2025). Provayblue (methylene blue) injection: prescribing information. American Regent, Inc. US National Library of Medicine. Accessed November 11, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6848e5-35ed-4046-b13c-3032b5ba3232
- Schirmer RH, Adler H, Pickhardt M, Mandelkow E (2011). "Lest we forget you--methylene blue...". *Neurobiol Aging*, *32*(12), 2325.e7–16. https://doi.org/10.1016/j.neurobiolaging.2010.12.012
- Iolascon A, Bianchi P, Andolfo I, et al (2021). Recommendations for diagnosis and treatment of methemoglobinemia. *Am J Hematol*, *96*(12), 1666–1678. https://doi.org/10.1002/ajh.26340
- Wright RO, Lewander WJ, Woolf AD (1999). Methemoglobinemia: etiology, pharmacology, and clinical management. *Ann Emerg Med*, *34*(5), 646–56. https://doi.org/10.1016/s0196-0644(99)70167-8
- Oz M, Lorke DE, Hasan M, Petroianu GA (2011). Cellular and molecular actions of Methylene Blue in the nervous system. *Med Res Rev*, *31*(1), 93–117. https://doi.org/10.1002/med.20177
- Ramsay RR, Dunford C, Gillman PK (2007). Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. *Br J Pharmacol*, *152*(6), 946–51. https://doi.org/10.1038/sj.bjp.0707430
- Mayer B, Brunner F, Schmidt K (1993). Inhibition of nitric oxide synthesis by methylene blue. *Biochem Pharmacol*, *45*(2), 367–74. https://doi.org/10.1016/0006-2952(93)90072-5
- Torchia A, Vari S, Onesti CE, et al (2025). A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas. *Front Pharmacol*, *16*, 1512966. https://doi.org/10.3389/fphar.2025.1512966
- Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB (2000). Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. *Br J Cancer*, *82*(2), 291–4. https://doi.org/10.1054/bjoc.1999.0917
- Patel PN (2006). Methylene blue for management of Ifosfamide-induced encephalopathy. *Ann Pharmacother*, *40*(2), 299–303. https://doi.org/10.1345/aph.1G114
- Abahssain H, Moukafih B, Essangri H, et al (2021). Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?. *J Oncol Pharm Pract*, *27*(1), 143–149. https://doi.org/10.1177/1078155220971843
- Law SK, Leung AWN, Xu C (2023). Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2-A Review. *Pharmaceuticals (Basel)*, *17*(1). https://doi.org/10.3390/ph17010034
- Tardivo JP, Del Giglio A, de Oliveira CS, et al (2005). Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. *Photodiagnosis Photodyn Ther*, *2*(3), 175–91. https://doi.org/10.1016/S1572-1000(05)00097-9
- Cardozo APM, da Silva DFT, Fernandes KPS, et al (2024). Antimicrobial photodynamic therapy with methylene blue and its derivatives in animal studies: Systematic review. *Photodermatol Photoimmunol Photomed*, *40*(4), e12978. https://doi.org/10.1111/phpp.12978
- Alasqah MN (2024). Efficacy of methylene blue-mediated antimicrobial photodynamic therapy on clinical and radiographic outcomes among patients with periodontal diseases: A systematic review and meta-analysis of randomized controlled trials. *Photodiagnosis Photodyn Ther*, *46*, 104000. https://doi.org/10.1016/j.pdpdt.2024.104000
- Saha BK, Burns SL (2020). The Story of Nitric Oxide, Sepsis and Methylene Blue: A Comprehensive Pathophysiologic Review. *Am J Med Sci*, *360*(4), 329–337. https://doi.org/10.1016/j.amjms.2020.06.007
- Ibarra-Estrada M, Kattan E, Aguilera-González P, et al (2023). Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. *Crit Care*, *27*(1), 110. https://doi.org/10.1186/s13054-023-04397-7
- Ballarin RS, Lazzarin T, Zornoff L, et al (2024). Methylene blue in sepsis and septic shock: a systematic review and meta-analysis. *Front Med (Lausanne)*, *11*, 1366062. https://doi.org/10.3389/fmed.2024.1366062
- Ng KT, Kwok PE, Lim WE, Teoh WY, Hasan MS, Zainal Abidin MF (2025). The use of methylene blue in adult patients with septic shock: a systematic review and meta-analysis. *Braz J Anesthesiol*, *75*(1), 844580. https://doi.org/10.1016/j.bjane.2024.844580
- Rodríguez-Lima DR, Rodríguez-Villegas A, Toro Egas JD, Bautista EMC (2026). The Effectiveness of Methylene Blue in Adult Shock: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. *J Clin Med*, *15*(12). https://doi.org/10.3390/jcm15124481
- Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G (2020). Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review. *Adv Ther*, *37*(9), 3692–3706. https://doi.org/10.1007/s12325-020-01422-x
- Arias-Ortiz J, Vincent JL (2024). Administration of methylene blue in septic shock: pros and cons. *Crit Care*, *28*(1), 46. https://doi.org/10.1186/s13054-024-04839-w
















